QIAGEN Launches Novel Integrated System for Collection, Stabilization, Transport, Storage and Isolation of Circulating Cell-free DNA
HILDEN, Germany and GERMANTOWN, Maryland, July 27, 2016 /PRNewswire/ --
PAXgene Blood ccfDNA enhances handling and workflow convenience for liquid biopsy applications in prenatal testing and cancer research
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new PAXgene« Blood ccfDNA Tube* for venous whole blood collection and room temperature stabilization of in-vivo circulating cell-free DNA (ccfDNA) profiles.
Together with the QIAamp Circulating Nucleic Acid Kit - the gold standard in manual extraction of circulating cell-free DNA - and upcoming new automated ccfDNA isolation on the QIAsymphony, PAXgene Blood ccfDNA builds a fully integrated and complete standardized system covering all pre-analytical workflow steps from blood collection, stabilization, transport, storage and isolation of high quality ccfDNA.
The new system contains a unique non-crosslinking reagent in the collection tube that ensures DNA remains unmodified. It prevents post-collection release of genomic DNA from white blood cells - resulting in improved ccfDNA yield recovery with less background DNA. A minimized release of contents of ruptured red blood cells into blood plasma (hemolysis) enables a maximized plasma recovery, particularly critical in cancer research. Combined with the proven plastic BD Vacutainer« Tube technology, customers will benefit from consistent blood draws and no more glass tube breakage during the workflow.
Click here for full press release
Public Relations: Dr. Thomas Theuringer Senior Director Public Relations +49-2103-29-11826 Email: firstname.lastname@example.org www.twitter.com/qiagen https://www.facebook.com/QIAGEN pr.qiagen.com
Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email:áir@qiagen.com ir.qiagen.com
SOURCE QIAGEN N.V.